Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
I-Mab
Pharma
Leqembi, Takeda, Roche—Fierce Pharma Asia
Uptake of Eisai's Leqembi is slower than expected. Takeda nixed three CAR-T candidates. Roche's C5 drug crovalimab nabbed its world-first nod.
Angus Liu
Feb 9, 2024 9:02am
AZ-Daiichi, Padcev, AbbVie—Fierce Pharma Asia
Sep 29, 2023 10:45am
Biocon, Henlius, Takeda and more—Fierce Pharma Asia
Sep 2, 2022 8:55am
Daiichi-Seagen, Roche-Jemincare, AbbVie-I-Mab—Fierce Pharma Asia
Aug 19, 2022 9:35am
J&J-Legend, Junshi, Vir-WuXi and more—Fierce Pharma Asia
May 27, 2022 9:53am
Merck, Sanofi, Fujifilm and more—Fierce Pharma Asia
Apr 22, 2022 8:42am
